Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) is expected to release its earnings data before the market opens on Wednesday, May 14th. Analysts expect Cartesian Therapeutics to post earnings of ($0.61) per share and revenue of $0.69 million for the quarter.
Cartesian Therapeutics Stock Performance
Shares of NASDAQ:RNAC opened at $10.57 on Wednesday. Cartesian Therapeutics has a 52 week low of $8.85 and a 52 week high of $41.87. The company has a market cap of $274.15 million, a PE ratio of -0.20 and a beta of 0.51. The firm has a 50 day simple moving average of $13.56 and a 200 day simple moving average of $17.31.
Analyst Ratings Changes
Several research analysts recently weighed in on the company. HC Wainwright reissued a "buy" rating and set a $40.00 price target on shares of Cartesian Therapeutics in a research report on Wednesday, April 9th. Needham & Company LLC reaffirmed a "buy" rating and set a $41.00 target price on shares of Cartesian Therapeutics in a research note on Wednesday, April 9th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $42.67.
View Our Latest Research Report on RNAC
Cartesian Therapeutics Company Profile
(
Get Free Report)
Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cartesian Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cartesian Therapeutics wasn't on the list.
While Cartesian Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
